<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519554</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200243</org_study_id>
    <secondary_id>2017-A00621-52</secondary_id>
    <nct_id>NCT04519554</nct_id>
  </id_info>
  <brief_title>Hysteroscopic Guided Endometrial Sampling: Prospective Comparison Between 5Fr and 7Fr Biopsy Forceps (HYSTEROBIO)</brief_title>
  <acronym>HYSTEROBIO</acronym>
  <official_title>Hysteroscopic Guided Endometrial Sampling: Prospective Comparison Between 5Fr and 7Fr Biopsy Forceps (HYSTEROBIO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indication for hysteroscopic guided biopsy compared to blind biopsy have been little&#xD;
      evaluated. However, this kind of biopsy is usually performed in many centre. They allow&#xD;
      exploration of uterine cavity but also to perform guided biopsies on the most suspicious&#xD;
      area. However, with 5Fr forceps, biopsy are often too small to conclude.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blind biopsies using Novak or Cormier cannula had limits. Demirkiran et al conclude on 673&#xD;
      women that histology was similar between biopsies and hysterectomy in only 67% of cases.&#xD;
      Others studies conclude thatit is difficult to conclude about focal disease with blind&#xD;
      biopsies.&#xD;
&#xD;
      A study compared blind biopsies to biopsy performed under hysteroscopic guidance in women&#xD;
      using Tamoxifene and conclude that guided biopsies were more specific (80% versus 68.9%) and&#xD;
      a better positive predictive value (68.9% versus 43.7%) for all kind of endometrial&#xD;
      pathologies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate ability to give a pathologic conclusion after 5Fr and 7Fr forceps biopsies</measure>
    <time_frame>During the pathologist's analysis</time_frame>
    <description>Evaluated by the number of cases on witch the biopsy allowed to conclude</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare histologic conclusions after 5 and 7Fr biopsies</measure>
    <time_frame>During the pathologist's analysis</time_frame>
    <description>Evaluated by Importance of collapse artifacts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare rate of ability to obtain pathologic conclusion on the sample after 5Fr and 7Fr forceps in endometrial carcinoma</measure>
    <time_frame>During the pathologist's analysis</time_frame>
    <description>The number of endometrial malignancies diagnosed histologically with either forceps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the rate of hysteroscopic failure due to cervical stenosis</measure>
    <time_frame>During the pathologist's analysis</time_frame>
    <description>The number of cases where hysteroscopy was not possible</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Biopsy</condition>
  <arm_group>
    <arm_group_label>5FR + 7FR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 5FR then 7 FR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7FR + 5FR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each woman is its own control and had biopsies with the 2 size of forceps. In this group first with 7FR then 5FR</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endometrial sampling</intervention_name>
    <description>Endometrial sampling with 2 different forceps</description>
    <arm_group_label>5FR + 7FR</arm_group_label>
    <arm_group_label>7FR + 5FR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Woman over 18 year-old with abnormal uterine bleeding (or endometrium thickness over&#xD;
             10mm) and risk factors of endometrial carcinoma, or endometrium thickness over 5mm in&#xD;
             a menopausal woman or abnormal uterine bleeding after 45 years old.&#xD;
&#xD;
               -  Woman who speak and understand french&#xD;
&#xD;
               -  Woman who give her written informed consent&#xD;
&#xD;
               -  Woman covered by french medical insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Pregnant or breastfeeding patient&#xD;
&#xD;
               -  Patient under guardianship, curators or safeguard of justice.&#xD;
&#xD;
               -  Patient participating in another ongoing study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perine CAPMAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Perinne CAPMAS</last_name>
    <phone>+33(0)145217701</phone>
    <email>perinne.capmas@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>AP-HP, Bicêtre Hospital</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial sampling hysteroscopy</keyword>
  <keyword>postmenopausal bleeding</keyword>
  <keyword>endometrial carcinoma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

